146 related articles for article (PubMed ID: 38405079)
1. A Simple Immunofluorescence Method to Characterize Neurodegeneration and Tyrosine Hydroxylase Reduction in Whole Brain of a
Chaurasia R; Ayajuddin M; Ratnaparkhi GS; Lingadahalli SS; Yenisetti SC
Bio Protoc; 2024 Feb; 14(4):e4937. PubMed ID: 38405079
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence microscopy-based sensitive method to quantify dopaminergic neurodegeneration in a
Ayajuddin M; Chaurasia R; Das A; Modi P; Phom L; Koza Z; Yenisetti SC
Front Neurosci; 2023; 17():1158858. PubMed ID: 37434762
[TBL] [Abstract][Full Text] [Related]
3. Sexual dysfunction precedes motor defects, dopaminergic neuronal degeneration, and impaired dopamine metabolism: Insights from
Koza Z; Ayajuddin M; Das A; Chaurasia R; Phom L; Yenisetti SC
Front Neurosci; 2023; 17():1143793. PubMed ID: 37025374
[TBL] [Abstract][Full Text] [Related]
4. Adult health and transition stage-specific rotenone-mediated
Ayajuddin M; Phom L; Koza Z; Modi P; Das A; Chaurasia R; Thepa A; Jamir N; Neikha K; Yenisetti SC
Front Mol Neurosci; 2022; 15():896183. PubMed ID: 36017079
[TBL] [Abstract][Full Text] [Related]
5. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
6. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
[TBL] [Abstract][Full Text] [Related]
7. Early Expression of Neuronal Dopaminergic Markers in a Parkinson's Disease Model in Rats Implanted with Enteric Stem Cells (ENSCs).
Parra-Cid C; Orozco-Castillo E; García-López J; Contreras-Figueroa E; Ramos-Languren LE; Ibarra C; Carreón-Rodríguez A; Aschner M; Königsberg M; Santamaría A
CNS Neurol Disord Drug Targets; 2020; 19(2):148-162. PubMed ID: 32303175
[TBL] [Abstract][Full Text] [Related]
8. Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease.
Roostalu U; Salinas CBG; Thorbek DD; Skytte JL; Fabricius K; Barkholt P; John LM; Jurtz VI; Knudsen LB; Jelsing J; Vrang N; Hansen HH; Hecksher-Sørensen J
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31704726
[TBL] [Abstract][Full Text] [Related]
9. SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta.
Aumann TD; Gantois I; Egan K; Vais A; Tomas D; Drago J; Horne MK
Exp Neurol; 2008 Oct; 213(2):419-30. PubMed ID: 18680743
[TBL] [Abstract][Full Text] [Related]
10. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
11. Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease.
Daviaud N; Garbayo E; Lautram N; Franconi F; Lemaire L; Perez-Pinzon M; Montero-Menei CN
Neuroscience; 2014 Jan; 256():10-22. PubMed ID: 24161279
[TBL] [Abstract][Full Text] [Related]
12. Knockdown transgenic Lrrk Drosophila resists paraquat-induced locomotor impairment and neurodegeneration: A therapeutic strategy for Parkinson's disease.
Quintero-Espinosa D; Jimenez-Del-Rio M; Velez-Pardo C
Brain Res; 2017 Feb; 1657():253-261. PubMed ID: 28041945
[TBL] [Abstract][Full Text] [Related]
13. Akt signal transduction dysfunction in Parkinson's disease.
Timmons S; Coakley MF; Moloney AM; O' Neill C
Neurosci Lett; 2009 Dec; 467(1):30-5. PubMed ID: 19800394
[TBL] [Abstract][Full Text] [Related]
14. Nanostructure lipid carriers enhance alpha-mangostin neuroprotective efficacy in mice with rotenone-induced neurodegeneration.
Sakamula R; Yata T; Thong-Asa W
Metab Brain Dis; 2022 Jun; 37(5):1465-1476. PubMed ID: 35353275
[TBL] [Abstract][Full Text] [Related]
15. The Impairments of α-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson's Disease.
Ramalingam M; Huh YJ; Lee YI
Front Neurosci; 2019; 13():1028. PubMed ID: 31611767
[TBL] [Abstract][Full Text] [Related]
16. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.
Stahl K; Mylonakou MN; Skare Ø; Amiry-Moghaddam M; Torp R
Brain Res; 2011 Mar; 1378():105-18. PubMed ID: 21236244
[TBL] [Abstract][Full Text] [Related]
17. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
18. Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson's Disease.
Eyer GC; Di Santo S; Hewer E; Andereggen L; Seiler S; Widmer HR
Cells; 2021 Nov; 10(12):. PubMed ID: 34943877
[TBL] [Abstract][Full Text] [Related]
19. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
20. GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area.
Sarabi A; Hoffer BJ; Olson L; Morales M
J Comp Neurol; 2001 Dec; 441(2):106-17. PubMed ID: 11745638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
